SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
18.64 EUR
+0.14 (+0.76%)
We assign a fundamental rating of 6 out of 10 to 1SXP. 1SXP was compared to 19 industry peers in the Life Sciences Tools & Services industry. 1SXP scores excellent on profitability, but there are some minor concerns on its financial health. 1SXP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
1SXP had a positive operating cash flow in the past year.
Each year in the past 5 years 1SXP has been profitable.
In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
1SXP has a better Return On Assets (9.62%) than 94.74% of its industry peers.
Looking at the Return On Equity, with a value of 17.03%, 1SXP belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
The Return On Invested Capital of 1SXP (13.86%) is better than 94.74% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1SXP is significantly above the industry average of 7.47%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.62% | ||
| ROE | 17.03% | ||
| ROIC | 13.86% |
ROA(3y)11.07%
ROA(5y)11.97%
ROE(3y)19.57%
ROE(5y)21.49%
ROIC(3y)15.67%
ROIC(5y)17.02%
1.3 Margins
1SXP has a better Profit Margin (15.07%) than 89.47% of its industry peers.
1SXP's Profit Margin has been stable in the last couple of years.
With an excellent Operating Margin value of 19.41%, 1SXP belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
1SXP's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 33.73%, 1SXP is doing worse than 63.16% of the companies in the same industry.
In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.41% | ||
| PM (TTM) | 15.07% | ||
| GM | 33.73% |
OM growth 3Y4.06%
OM growth 5YN/A
PM growth 3Y0.29%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1SXP is creating value.
Compared to 1 year ago, 1SXP has more shares outstanding
The debt/assets ratio for 1SXP has remained at the same level compared to a year ago.
2.2 Solvency
1SXP has a debt to FCF ratio of 1.69. This is a very positive value and a sign of high solvency as it would only need 1.69 years to pay back of all of its debts.
1SXP's Debt to FCF ratio of 1.69 is amongst the best of the industry. 1SXP outperforms 100.00% of its industry peers.
1SXP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
1SXP has a better Debt to Equity ratio (0.09) than 94.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | N/A |
ROIC/WACC1.69
WACC8.22%
2.3 Liquidity
1SXP has a Current Ratio of 1.57. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP has a Current ratio of 1.57. This is in the better half of the industry: 1SXP outperforms 78.95% of its industry peers.
A Quick Ratio of 1.16 indicates that 1SXP should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.16, 1SXP is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -3.00% in the last year.
1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.90% yearly.
The Revenue has been growing slightly by 2.86% in the past year.
Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 13.84% on average per year.
EPS 1Y (TTM)-3%
EPS 3Y13.9%
EPS 5YN/A
EPS Q2Q%-3.23%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
3.2 Future
1SXP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.13% yearly.
The Revenue is expected to grow by 8.14% on average over the next years. This is quite good.
EPS Next Y3.25%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
EPS Next 5Y11.13%
Revenue Next Year2.31%
Revenue Next 2Y5.51%
Revenue Next 3Y7.02%
Revenue Next 5Y8.14%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.22, the valuation of 1SXP can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of 1SXP indicates a somewhat cheap valuation: 1SXP is cheaper than 78.95% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of 1SXP to the average of the S&P500 Index (25.65), we can say 1SXP is valued slightly cheaper.
A Price/Forward Earnings ratio of 15.93 indicates a correct valuation of 1SXP.
1SXP's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. 1SXP is cheaper than 78.95% of the companies in the same industry.
1SXP is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.45, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.22 | ||
| Fwd PE | 15.93 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP indicates a somewhat cheap valuation: 1SXP is cheaper than 78.95% of the companies listed in the same industry.
1SXP's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. 1SXP is more expensive than 68.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.05 | ||
| EV/EBITDA | 10.66 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)5.92
PEG (5Y)N/A
EPS Next 2Y8.71%
EPS Next 3Y10.5%
5. Dividend
5.1 Amount
1SXP has a yearly dividend return of 0.87%, which is pretty low.
1SXP's Dividend Yield is a higher than the industry average which is at 0.73.
With a Dividend Yield of 0.87, 1SXP pays less dividend than the S&P500 average, which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.87% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.33% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.33%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
FRA:1SXP (11/25/2025, 5:29:46 PM)
18.64
+0.14 (+0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.81B
Revenue(TTM)975.68M
Net Income(TTM)147.00M
Analysts78.95
Price Target29.58 (58.69%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.87% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.33%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.82%
PT rev (3m)-1.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.65%
EPS NY rev (3m)-1.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.61%
Revenue NY rev (1m)-0.3%
Revenue NY rev (3m)-1.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.22 | ||
| Fwd PE | 15.93 | ||
| P/S | 2.88 | ||
| P/FCF | 55.05 | ||
| P/OCF | 13.76 | ||
| P/B | 3.25 | ||
| P/tB | 3.37 | ||
| EV/EBITDA | 10.66 |
EPS(TTM)0.97
EY5.2%
EPS(NY)1.17
Fwd EY6.28%
FCF(TTM)0.34
FCFY1.82%
OCF(TTM)1.35
OCFY7.27%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)5.92
PEG (5Y)N/A
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.62% | ||
| ROE | 17.03% | ||
| ROCE | 16.98% | ||
| ROIC | 13.86% | ||
| ROICexc | 14.4% | ||
| ROICexgc | 14.81% | ||
| OM | 19.41% | ||
| PM (TTM) | 15.07% | ||
| GM | 33.73% | ||
| FCFM | 5.23% |
ROA(3y)11.07%
ROA(5y)11.97%
ROE(3y)19.57%
ROE(5y)21.49%
ROIC(3y)15.67%
ROIC(5y)17.02%
ROICexc(3y)16.17%
ROICexc(5y)17.75%
ROICexgc(3y)16.77%
ROICexgc(5y)18.76%
ROCE(3y)19.22%
ROCE(5y)20.88%
ROICexgc growth 3Y-8.55%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.4%
ROICexc growth 5YN/A
OM growth 3Y4.06%
OM growth 5YN/A
PM growth 3Y0.29%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 204% | ||
| Cap/Sales | 15.68% | ||
| Interest Coverage | 11.79 | ||
| Cash Conversion | 77.17% | ||
| Profit Quality | 34.69% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | N/A |
F-Score5
WACC8.22%
ROIC/WACC1.69
Cap/Depr(3y)291.66%
Cap/Depr(5y)279.8%
Cap/Sales(3y)17.76%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.94%
Profit Quality(5y)27.76%
High Growth Momentum
Growth
EPS 1Y (TTM)-3%
EPS 3Y13.9%
EPS 5YN/A
EPS Q2Q%-3.23%
EPS Next Y3.25%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
EPS Next 5Y11.13%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
Revenue Next Year2.31%
Revenue Next 2Y5.51%
Revenue Next 3Y7.02%
Revenue Next 5Y8.14%
EBIT growth 1Y11.76%
EBIT growth 3Y18.46%
EBIT growth 5YN/A
EBIT Next Year46.93%
EBIT Next 3Y24.15%
EBIT Next 5Y18.78%
FCF growth 1Y-26.72%
FCF growth 3Y33.53%
FCF growth 5YN/A
OCF growth 1Y-5.2%
OCF growth 3Y19.39%
OCF growth 5YN/A
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for 1SXP stock?
The Price/Earnings (PE) ratio for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 19.22 and the Price/Book (PB) ratio is 3.25.
Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?
The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 3 / 10 and the dividend payout ratio is 16.33%.